management of NSCLC

Several oncogenic driver alterations are now used as standard in the selection of treatment regimens in non-small cell lung cancer (NSCLC), such as EGFR, ALK, ROS1, BRAF, HER2 and NTRK, with more being discovered.

This expert-led program aims to improve the individualised management of NSCLC through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies.

There will also be guidance on integrating shared decision making into your clinical practice drawing on insights from a patient on how best to communicate.

This program is aimed at global oncologists, pathologists and those treating patients with NSCLC.

For CME-accredited activities, look for the badge

Watch a brief introduction to the program by Fernando Lopez-Rios, Program Director

CME-accredited activities

The importance of shared decision making

eLearning module and downloadable PDF

(0.5 AMA PRA Category 1 Credits™)

Detecting and targeting NTRK fusions in NSCLC

Clinical pathway tool

(0.5 AMA PRA Category 1 Credits™)